Nordic Pharmaceutical Company SAC

Nordic Pharmaceutical Company SAC is a Peruvian pharmaceutical company established on February 5, 2002, with its headquarters located at Jr. Patricio Iriarte 279, Urb. Santa Catalina, La Victoria, Lima. The company specializes in the wholesale distribution of pharmaceutical and medicinal products, cosmetics, and personal care items. Over the years, Nordic Pharmaceutical has built a solid presence in both the public institutional sector and the private market, with an annual turnover of approximately nine million dollars.

The company's portfolio encompasses six key therapeutic areas: cardiovascular, hematology, oncology, gastroenterology, anti-infectives and retrovirals, and urology. Nordic Pharmaceutical is committed to providing accessible, high-quality medications to patients in Peru, collaborating closely with healthcare professionals to ensure effective therapeutic solutions.

Nordic Pharmaceutical Company SAC operates a centralized distribution network from its headquarters in Lima, Peru. While specific details about warehouse locations and logistics capabilities are not publicly disclosed, the company's extensive import activities suggest a well-established infrastructure capable of managing a diverse product portfolio. The distribution network primarily serves the Peruvian market, ensuring that medications reach various healthcare facilities and pharmacies across the country.

Nordic Pharmaceutical Company SAC functions as a primary wholesaler in Peru's pharmaceutical supply chain. The company imports finished pharmaceutical formulations from international suppliers, including a significant number from India, and distributes these products to healthcare providers and pharmacies throughout Peru. By focusing on the wholesale distribution of imported finished formulations, Nordic Pharmaceutical plays a crucial role in ensuring the availability of a wide range of therapeutic options to meet the diverse needs of the Peruvian healthcare system.

Nordic Pharmaceutical Company SAC's sourcing strategy exhibits a high degree of concentration, with a significant portion of its imports originating from a select group of Indian suppliers. The top five suppliers account for 100% of the company's imports, indicating a strategic choice to maintain strong, stable relationships with these partners. This concentrated sourcing approach can lead to benefits such as favorable pricing, consistent product quality, and reliable supply chains. However, it also presents risks, including potential vulnerabilities to supply disruptions or changes in supplier dynamics. The company's reliance on a limited number of suppliers necessitates robust risk management strategies to mitigate potential impacts on operations.

The resilience of Nordic Pharmaceutical Company SAC's supply chain is closely tied to its concentrated sourcing model. While the company benefits from strong relationships with its primary suppliers, this dependence also means that any disruptions—such as production issues, regulatory changes, or geopolitical events affecting supplier countries—could significantly impact the company's ability to maintain a consistent product supply. To enhance supply chain resilience, Nordic Pharmaceutical may consider diversifying its supplier base, establishing contingency plans, and closely monitoring the regulatory compliance and operational stability of its key suppliers.

The concentrated sourcing pattern of Nordic Pharmaceutical Company SAC positions the company to leverage strong partnerships with its primary suppliers, potentially securing favorable terms and ensuring consistent product quality. For Indian exporters, this presents an opportunity to strengthen their relationships with Nordic Pharmaceutical by offering high-quality products, competitive pricing, and reliable delivery schedules. However, the risks associated with supply chain concentration mean that both parties must collaborate closely to develop contingency plans and ensure the continuity of supply, thereby enhancing the overall stability and competitiveness of Nordic Pharmaceutical in the Peruvian market.

In Peru, the regulatory authority responsible for overseeing pharmaceutical imports and ensuring the safety and efficacy of medications is the General Directorate of Medicines, Supplies, and Drugs (DIGEMID), which operates under the Ministry of Health. DIGEMID is tasked with evaluating and approving pharmaceutical products, including those imported from countries like India. The regulatory framework governing pharmaceutical imports in Peru includes requirements for Good Manufacturing Practice (GMP) certification, product registration, and compliance with labeling and packaging standards. These regulations are designed to protect public health by ensuring that all pharmaceutical products meet established quality standards before they are distributed within the country.

Import licensing requirements in Peru stipulate that all pharmaceutical products, including those imported by companies like Nordic Pharmaceutical Company SAC, must be registered with DIGEMID prior to distribution. This registration process involves submitting detailed product information, including evidence of GMP certification from the manufacturing facility. DIGEMID recognizes GMP certifications from reputable international bodies, such as the World Health Organization (WHO) and the Pharmaceutical Inspection Co-operation Scheme (PIC/S), facilitating the acceptance of products manufactured under these standards. Additionally, companies must obtain wholesale distribution authorization to legally distribute pharmaceutical products within Peru.

Pharmaceutical products imported into Peru are subject to stringent quality control measures, including batch testing and stability studies, to ensure their safety and efficacy. Labeling requirements mandate that product information be provided in Spanish, the official language of Peru, and include details such as the product name, active ingredients, dosage form, manufacturer information, and expiration date. Serialization mandates may also apply, requiring unique identifiers on packaging to facilitate traceability and prevent counterfeit products from entering the market. These measures are essential for maintaining public trust and ensuring the integrity of the pharmaceutical supply chain.

Between 2024 and 2026, Peru has implemented several regulatory changes affecting pharmaceutical imports. Notably, the Ministry of Health has intensified inspections and quality control measures for imported medications, leading to the withdrawal of thousands of cancer treatment vials due to contamination issues. Additionally, there have been updates to the requirements for GMP certification, with DIGEMID now recognizing certifications from a broader range of international bodies. These changes aim to enhance the safety and quality of pharmaceutical products available in Peru, impacting importers like Nordic Pharmaceutical Company SAC.

Nordic Pharmaceutical Company SAC's focus on importing products in the cardiovascular, nutritional supplements, and medical devices & diagnostics categories aligns with the company's strategic objectives to address prevalent health concerns in Peru. The cardiovascular category, comprising 63.4% of imports, reflects the high incidence of heart-related diseases in the country. Nutritional supplements (20.0%) and medical devices & diagnostics (16.6%) are also critical areas, addressing the growing demand for preventive healthcare and diagnostic tools. By concentrating on these therapeutic areas, Nordic Pharmaceutical aims to meet the specific health needs of the Peruvian population, thereby enhancing its market position and fulfilling its mission to provide accessible, high-quality healthcare solutions.

Nordic Pharmaceutical Company SAC's sourcing strategy emphasizes the importation of generic drug formulations, primarily from India, to offer cost-effective therapeutic options to the Peruvian market. The company's preference for finished pharmaceutical formulations over raw active pharmaceutical ingredients (APIs) allows for a more streamlined supply chain and ensures that products are ready for distribution upon arrival. India's well-established pharmaceutical manufacturing sector, known for its adherence to international quality standards, makes it a reliable source for these formulations. This sourcing approach enables Nordic Pharmaceutical to maintain a diverse product portfolio while managing costs effectively.

Based on its product mix, Nordic Pharmaceutical Company SAC primarily serves the wholesale distribution segment of the Peruvian pharmaceutical market. By importing a diverse range of pharmaceutical products, including generic formulations, nutritional supplements, and medical devices, the company supplies these items to various healthcare providers, pharmacies, and institutions across Peru. This positioning allows Nordic Pharmaceutical to play a pivotal role in ensuring the availability of essential healthcare products, thereby contributing to the overall health infrastructure of the country.

There is a realistic opportunity for new Indian suppliers to collaborate with Nordic Pharmaceutical Company SAC, given the company's concentrated sourcing pattern and the high demand for pharmaceutical products in Peru. Potential gaps in Nordic Pharmaceutical's current sourcing include the need for additional suppliers to mitigate risks associated with supply chain concentration and to meet the growing demand for specific therapeutic areas. Indian exporters can capitalize on this opportunity by offering high-quality products, competitive pricing, and reliable delivery schedules, thereby establishing strong partnerships with Nordic Pharmaceutical and expanding their presence in the Peruvian market.

Indian exporters seeking to supply Nordic Pharmaceutical Company SAC and the Peruvian market must ensure that their products comply with Peru's regulatory requirements. This includes obtaining GMP certification from recognized international bodies such as WHO or PIC/S, registering products with DIGEMID, and adhering to labeling and packaging standards in Spanish. Additionally, exporters should be prepared to provide documentation supporting the safety, efficacy, and quality of their products, as these are critical factors in the approval process. Maintaining consistent product quality and compliance with regulatory standards is essential for establishing and sustaining business relationships in Peru.

To establish a successful partnership with Nordic Pharmaceutical Company SAC, Indian exporters should initiate contact by providing detailed product information, including certifications, quality control measures, and compliance with Peruvian regulations. Participating in tenders and responding to requests for proposals can also be effective strategies to engage